HYPR:NASDAQHyperfine, Inc. Analysis
Data as of 2026-05-29 - not real-time
$1.57
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Hyperfine, Inc. has posted an impressive 83% year‑over‑year revenue increase to $3.9 million in Q1 2026, with gross margins expanding to just over 50% while the net loss narrowed to $0.09 per share. The company’s cash balance of $40.8 million comfortably exceeds its $13.1 million debt, giving it a solid liquidity cushion despite negative operating cash flow. Analyst sentiment is bullish, with three analysts rating the stock a strong buy and consensus price targets around $2.00, implying roughly a 38% upside from the current $1.565 price. However, the stock trades at a price‑to‑book of 4.48 and a price‑to‑sales multiple above 10, suggesting the market is pricing in future growth expectations.
Technical indicators show a bullish alignment of the 20‑day, 50‑day and 200‑day SMAs, and the price is holding above the identified support of $1.37, but the MACD has turned bearish and volume is on a decreasing trend, indicating short‑term pressure. A beta of 2.59 and 30‑day volatility above 80% point to pronounced price swings, while a recent max drawdown of nearly 60% underscores downside risk. Liquidity is constrained, with daily volume far below its 10‑day average, raising concerns about trade execution. Overall, the stock offers strong growth catalysts but remains highly volatile and speculative.
Technical indicators show a bullish alignment of the 20‑day, 50‑day and 200‑day SMAs, and the price is holding above the identified support of $1.37, but the MACD has turned bearish and volume is on a decreasing trend, indicating short‑term pressure. A beta of 2.59 and 30‑day volatility above 80% point to pronounced price swings, while a recent max drawdown of nearly 60% underscores downside risk. Liquidity is constrained, with daily volume far below its 10‑day average, raising concerns about trade execution. Overall, the stock offers strong growth catalysts but remains highly volatile and speculative.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near support level of $1.37
- Decreasing volume and bearish MACD histogram
- High short‑term volatility (beta 2.59, 30‑day vol 84%)
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Robust revenue growth (+83% YoY) and expanding gross margin
- Analyst consensus strong‑buy with ~38% upside target
- Strong cash position relative to debt
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Strategic market expansion of portable MRI technology
- Potential for improved operating efficiencies and profitability
- Sustained industry demand for decentralized imaging solutions
Key Metrics & Analysis
Financial Health
Revenue Growth82.60%
Profit Margin-226.88%
P/E Ratio-4.6
ROE-89.78%
ROA-38.19%
Debt/Equity38.19
P/B Ratio4.5
Op. Cash Flow$-27707000
Free Cash Flow$-16274000
Industry P/E27.8
Technical Analysis
TrendBullish
RSI53.1
Support$1.37
Resistance$1.93
MA 20$1.62
MA 50$1.39
MA 200$1.25
MACDBearish
VolumeDecreasing
Fear & Greed Index93.39
Valuation
Target Price$2.17
Upside/Downside38.45%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta2.59
Volatility84.32%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.